Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The only "Disgusting scam" is the one that an itty bitty tiny teeny weeny cabal keeps trying desperately to sell to IFUS shareholders, who along with the market now understands is obviously going to go Bankrupt covering the illegal naked overseas IFUS shorts the SEC is targeting on all US stocks now, while Schwab is forced to cover their shorts of the naked short hedge funds that were dumb enough to expose who they are to us shareholders.
Big, Huge, major mistake.
Your post history and mine proves I have been right about IFUS and the anti-Ifus cabal has been wrong since day one.
Yep, and it's nice to see signs of Intelligent posting here again (been a long while) like I see in the post I am replying to:
NFTM shorts are screwed, as the Cost to borrow is up over 5000% and there are only 900 share available to borrow
1000 shares sold short 4 days ago, was 100% short volume, and only 900 left to borrow at the open today.
https://fintel.io/ss/us/nftm
As FED Powell says "F*ckTheirPuts" LOLOLOL
Today is triple witching Options expiration, so the market is acting goofy after making all time highs a day ago because of the 1/2% FED rate reduction.
One way to lock the shorts out, is to put all shares up for sale at $10/share or more.
This is going to moon on any news.
$BIXT Major news
https://finance.yahoo.com/news/bioxytrans-medical-breakthrough-fighting-viruses-133500730.html
Bioxytran's Medical Breakthrough in Fighting All Viruses
BioXyTran, Inc.
Thu, September 19, 2024 at 8:35 AM CDT 6 min read
In This Article:
BIXT
+28.37%
Breakthrough was validated in the latest journal article
Galectins are essential for viral entry and a new target for drug development
Carbohydrates were shown to neutralize viruses
Blocking galectins could be the most efficient way to prevent and treat viruses potentially impacting the vaccination and antiviral markets
BOSTON, MA / ACCESSWIRE / September 19, 2024 / BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced a medical breakthrough in virology that was validated in a peer-reviewed medical journal article. The European Society of Medicine published a peer-reviewed article detailing a study which shows how Bioxytran's leading drug candidate, Prolectin-M, stops COVID-19 and other viruses in their tracks. The study used advanced Nuclear Magnetic Resonance (NMR) spectroscopy to reveal how this drug works by blocking a protein called galectin, which helps viruses attach to cells. The discovery could impact both the vaccination and antiviral markets, which combined are estimated at approximately $147 billion according to Grandview Research and Statista.
https://esmed.org/MRA/mra/article/view/5616
The peer-reviewed article identified Galectin-3 as a crucial "glue" that helps the virus attach to and enter human cells by sticking to the ACE2 receptor, altering our existing understanding of how viral infections occur. The discovery was proven using NMR Spectroscopy which is extremely precise compared to the 50-year-old ELISA tests which was used to establish virology's initial foundation on how viruses worked and interacted with antivirals. The report proved that by blocking this process, the drugs prevented the virus from entering the cells, which means the virus couldn't make people sick. The double-blind placebo controlled clinical studies showed that these drugs were 100% effective in reducing symptoms and eliminating the virus in 2 peer-reviewed clinical trials.
The study also pointed out that galectins, located on the spike protein of the virus, are an excellent target for drugs because it doesn't change much, making it easier to stop the virus from attaching to cells. This could make these drugs effective against a wide range of viruses, not just COVID-19.
"This discovery might be one of the most significant advancements in virology," said Dr. David Platt, CEO of Bioxytran. "In our first case study to make a SARS-CoV-2 antiviral drug, it appears we have on our hands the first truly broad-spectrum antiviral that may operate across different families of viruses. We believe we have discovered a reproducible method that could potentially be used to create many antiviral drugs that could potentially quickly fight off new viruses, even those that mutate rapidly. We believe our approach represents a new era in antiviral drug development. With the help of advanced technology and Artificial Intelligence (AI), it is now possible to design antiviral drugs that could potentially neutralize any virus. This discovery could change the way we treat viral diseases and even chronic illnesses like cancer. We believe major advancements in virology with this new tech will be measured in months instead of years and decades as has been the case in the past."
"Using this new platform technology could revolutionize how we create new antiviral treatments," said Dr. Kevin Mayo, Professor of the University of Minnesota.
"Traditional methods of developing antivirals and vaccines are not precise and involve a lot of trial and error. Their weakness has always been their reliance on the immune system to work properly and everyone's immune system is unique.
Our results show we can neutralize viruses without the help of the immunes system making our system incredibly reliable. This breakthrough opens a new chapter in fighting viral diseases, providing hope for treating not only SARS-CoV-2 but other highly pathogenic and contagious viruses influenced by galectins. This may be the crown jewel of virology and a few more tests on other viruses could prove it."
Antiviral and Vaccination Market
The global antiviral drugs market is valued at $72.84 billion according to Grandview Research. The global vaccine market is valued at $74.12 billion in 2024 by Statista. Combined the markets total approximately $147 billion. The growth drivers in antivirals are the increasing prevalence of viral infections like HIV, hepatitis, and influenza, along with the increase in antiviral drug development and treatments. The market is dominated by drugs for HIV, hepatitis C, and influenza, with HIV antivirals holding a substantial market share due to the ongoing need for effective treatments. Additionally, there is a growing demand for broad-spectrum antiviral drugs that can be rapidly deployed in response to emerging viral threats.
The COVID-19 pandemic accelerated vaccine development and distribution. New technological advancements in mRNA technology, protein-based vaccines, and microarray patches are enhancing efficacy, stability and accessibility of vaccines. Growing indications include HPV, pneumococcal infections, and RSV. Global health initiatives to combat malaria and tuberculosis are also driving the development of new vaccines.
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company pioneering a library of novel complex carbohydrate structures using artificial intelligence software that interprets the Nuclear Magnetic Resonance imaging of druggable targets like the galectin fold to create a rational drug design. The leading drug candidates vetted by in vitro testing, are capable of neutralizing viruses. The peer-reviewed discovery of the galectin fold located on the spike proteins of viruses such as COVID-19, RSV, and H1N1 demonstrate there exists a conserved region on the spike in which Bioxytran's molecules achieve virus neutralization. The extent of the carbohydrate structure's ability to neutralize untested viruses is unknown just like the initial discovery of antibiotics last century and its ability to treat a broad spectrum of bacterial infections. Applications of this platform technology extend to the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran's other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
SOURCE: BioXyTran, Inc.
View the original press release
see on accesswire.com
https://www.accesswire.com/920259/bioxytrans-medical-breakthrough-in-fighting-all-viruses
You must enjoy being wrong all the time?
I enjoy the laughs, thanks.
I have never seen so many freaked out panicked shorts in a stock since Game stop in 2021 as I am seeing here in $IFUS.
And who is saying I am not and have not done both, many times?
I have picked and rode stocks that rallied 999,900%
CNNA is on the menu for an easy 1000%++
I called the buy the day one stock I married ran from .0021 to .345 in 8 trading days with a 2 Billion share float. The rally was based on my DD I shared. I shared it after all the idiots sold.
Crickets always make a lot of noise, until something happens
Dumb and dumber post content I am replying to has confirmed that some people have no business in the stock market.
You claim you are selling to MM's? LMAO. Why would MM's buy your CNNA shares? If they were short the float? Maybe.
If they are buying your shares, you should not be selling, because it would be super bullish for MMs to be buying, for any reason, especially at 1000% above the EM market low prices.
What you fail to comprehend is the "hype' and Hoopla has not even begun missy.
The shorts on IFUS sound crazy-desperate, like kids that got their candy taken away paying the piper $$$$$ for the short sighted shorts they can not cover with out going broke. As Spock's father Surek once said "Lessons are often Expensive"
That is exactly what weak hands and weak minds say.
CNNA is up nearly 1000% in EM land with audited financials in a form 10 coming and the market gets it, that is why the stock is up about 100% from the Early E-Market lows
Just to be clear, are you trying to claim no was fooled and thus no one was willing to hire you to post lies here about $IFUS
GM folks. A lot of major improvements have been made and more seem to be coming almost daily on the IFUS website.
Check them out. http://www.impactfusionbrands.com
Some of the pages and images are dynamic, with zoom capabilities. It seems to be a work in progress, so check back frequently.
The original human supplement line is back in stock. I have used the $IFUS Intact Digest supplement daily since 2013, and there is nothing else like it on the market.
It is great for muscle recovery from intense exercise, great for digestive gut health, heart health, Liver health, great for muscle cramps, and so much more. It basically supplies the body with the organic minerals that are missing in today's foods, due to mineral depleted soils our food is grown in. It also helps people avoid constipation. IFUS Shorts should have tried it. It is too late for them now, because they are stuck short, and burning cash like crazy.
I used $IFUS Intact Digest for 8 years while on a chemo drug for RA to avoid Chemo constipation. I still use it daily. Got any questions just ask.
Orders can be placed on line.
Also a Pharmacist, Dr. Pruitt that owns his own pharmacies in Tennessee has a weekly TV ask the pharmacist show.
He is now an IFUS Intact Digest, stocking Distributor
IFUS Cattle feed and IFUS organic Mulch, Supreme AG are being sold, and the University Consortium that the EPA and USDA and NIH federal funding, and State of Louisiana funded (Is funding) is studying what IFUS has figured out, namely De-polymerizing Lignin in Sugar cane waste Ag Fiber, "The Holy Grail" to make the SGP+(tm) cattle feed and Organic Mulch, that have been proven to be game changers for customers already, is underway, to produce data, confirming the known science behind the real world science results, we see in the field trials.
There is also a live stock price ticker and menu on the home page that takes folks to the IFUS stock news page list at OTCMarkets where all the steady shareholder news that was not paid PRs (so many have never seen that news yet) or in SEC filings (yet, hint?) is located.
Schwab still shows zero shares available to borrow for IFUS.
IFUS shorts are screwed now.
Yes, but only for the US market.
Ndtp was still a CE/EM shell save and it ran to $10.50/share several times with a 29K float, and hit a billion share market cap. All $NFTM needs is an operating NFT ebay-of-nft operating site now. And financials showing cash and assets?
The brokers like Fidelity will not let you place an order over about .25/share
This is still trading as VBIVQ , with volume near .02/share
Crime by Market Manipulation is legal for MM's, that is why their acronym is MM.
Joe Kennedy in 1933 was assigned by FDR to create the SEC and invented shorting to line his pockets and avoid another 1929 market crash.
Today's Supreme Court believes the SEC is an illegal rouge agency, since the US Congress is the only one with constitutional authority, and not a US President.
The MM's are trying to force bid support stacking and gap closing and if needed trying to draw down the ask prices, by blocking us placing bids near the ask.
The MM's can also eat shares at the bid, and use them to walk down the ask
Now if everyone teams up and places L-2 orders and stacks and walks up the bids retail can push back.
MM's can eat all the sells to the bid and refuse to fill out orders as well.
Knowledge is power...
We need news now or dedicated longs willing to walk the bid up in steps, until we claim $1.00 as the bid (which was .01 before the R/S)
No new shares can hit this float for 2 years.
Old day traders trick wash trade, or moving their own shares from one account to another, or MM's playing wash trade game to trigger sellers.
US Brokers are blocking bids near the ask because of the spread (they likely created), and the minimum bid to show on L-2 is 10,000 down under. It will take a team effort to take and hold $1/share and hold the bid there and higher. It can be done, but will be way easier with news or a few whales that like NFTM.
The float is not changing for 2 years going forward.
I do know that Tanked-Hank and the nonsense posts by trash-n-bash wolves in sheep's clothing were all dead wrong here, like I said, and Babl, is now $NFTM and the CEO got it all done, in spite of endless Finra delays.
I just discovered the ticker change Friday.
So the market, except a few of us, have no clue what has happened or going on here yet. We need to get the word out. If we can take the high ground at $1/share and hold the bid there, this ran make it to $10+/share with real PR news..., because of the itty bitty tiny float.
That float ain't changing for at least 2 years, because the restricted shares can not be sold, once issued, for 2 years.
I am super picky about OTC stocks I marry. I have been in several that did large up to 4000:1 R/S and 2 of them Tgtx, Opxs went to Nasdaq and Tgtx hit over $50/share in 2021. Until we open the box and see what's inside.
If they raise cash with fixed priced restricted shares, and get the NFT world excited, this could make a moon run,
OTC Markets says $NDTP is not a shell. Financials say it is not a shell. Guess you forgot to check before mouthing off here?
Awesome, factual, true DD can also be found here, and in the post I am replying to, about $SAPX:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174300820
Everything else is just short seller sour grapes, and bottom feed BS
That is the most intelligent & accurate post here in over a week sir.
That is 100% correct:
The tide has turned for $BIXT now. First come first serve for bottom feeders, Here is why:
$BIXT TA share data was updated, and the OS share count is now down 50%
The Market cap is now down 50% from $14 Million dollars to $7 Million dollars
And they recently scored a HEME-Foundation 10 Million dollar grant (No debt, no share dilution deal)
to fund completion of the $BIXT synthetic oxygen carrier, that has a 5 year shelf life,
and that can be added to blood plasma in emergencies (when there is no time to do tests and blood type tests, and seconds
can me life or death), to ensure the organs, heart and brain get plenty of oxygen.
The $BIXT synthetic oxygen carrier molecule is so small
it can easily by pass blood clots, while hemoglobin is too large to get past the blood clots.
It will be a game changing life saver in operating rooms, emergency rooms and mash casualty disaster events.
All on top of the having the worlds only Galectin inhibitor that is a non-toxic oral pill, that can stop 60+ viruses from infected human cells, and has world wide PCT patent coverage, and has phase III US FDA IND drug trial approval for long haul Covid, has been tested as a skin cream that stops shingles sores, and is ready for a phase III Covid trial in India.
http://www.bixytaninc.com
NEW BIXT snippet -
$BIXT TA share data was updated, and the OS share count is now down 50%
The Market cap is now down 50% from $14 Million dollars to $7 Million dollars
And they recently scored a HEME-Foundation 10 Million dollar grant (No debt, no share dilution deal)
to fund completion of the $BIXT synthetic oxygen carrier, that has a 5 year shelf life,
and that can be added to blood plasma in emergencies (when there is no time to do tests and blood type tests, and seconds
can me life or death), to ensure the organs, heart and brain get plenty of oxygen.
The $BIXT synthetic oxygen carrier molecule is so small
it can easily by pass blood clots, while hemoglobin is too large to get past the blood clots.
It will be a game changing life saver in operating rooms, emergency rooms and mash casualty disaster events.
All on top of the having the worlds only Galectin inhibitor that is a non-toxic oral pill, that can stop 60+ viruses from infected human cells, and has world wide PCT patent coverage, and has phase III US FDA IND drug trial approval for long haul Covid, has been tested as a skin cream that stops shingles sores, and is ready for a phase III Covid trial in India.
http://www.bixytaninc.com
NEW BIXT snippet -
I am calling BS on your reply.
As they say in Texas, it ain't braggin' if you can deliver the goods...
$IFUS delivers. 100% customer retention rate
$IFUS Supreme AG Mulch, all organic, all natural Mulch / fertilizer, trials are showing double the growth rate of the best know products, insect pest free growth in soils plants and peach trees would not grow in, will grow using Supreme AG made and sold only by $IFUS. The product is proprietary, sole source, but is super cost effective and the supply is endless. http://impactfusionbrands.com Call Marc for trial samples folks Phone: 1-800-775-4130 or email
impactfusionintl@gmail.com
$NVDA $GME $AMC $TSLA #Stockstobuy #StocksInFocus #OTC $MULN $KIRK $NIOS $NVDA $GME $AMC $TSLA $KITL $CGRA $TGLO $BLLB $VDRM $BLEG $BLFR $BLLB $CISO $CLNV $CNER $CSCO $DBMM $ELTP $ENZC $FDCT $GNS $GOLD $GVSI $HHSE $HMBL $HPNN $HYMC $KATX $KITL $KRTL $LWLG $MMTMF $MMY $MMM $MSFT $MULN $NHMD $NWBO $RGBP $RNVA $SMME $SRNW $STAL $TGT $TGTX $OPK $OPXS $TSLA $WMT $YCRM $ZHUD $GBTC $TCEHY $LKNCY $NTDOY $RHHBY $LTCN $BEGI $YCRM $NWBO $GVSI $HMBL $DZNY $BLEG $INBS $PRSO $JAGX $SNTI $JAN $ASTR $RDRSF $RGBP $EPAZ $BIXT $IFUS $MSOS $CCHW $CCHWF $GRAM $GRAMF $VRNO $VRNOF $GDNSF $TRUL $TCNNF $AYR $AYRWF $CURA $CUR $CBDLLF $TLRY $CGC $HEXO $PPCB $HEMP $XCPL $PHIL $MCOA $BANT $PVSP $GRLT $INND $BBRW $MMEX $TONR $ICNM $IDVV $GBTC $TCEHY $LKNCY $DIDIY $SONG $MCLE $ETCG $GDLC $TOELY $NWBO $GVSI $BEGI $TMGI $NLST $INBS $TCON $INVO $MRAI $IONM
$EVKRF $GME $GOLD $GVSI $IDVV $KATX
$LITOF $LQMT $LTHM $LTUM $LWLG
$MMM $MMTMF $MMY $NBIO $NHMD
$NVDA $NWBO $PEIMF $RDHL $RIVN
$RNVA
Great post great stock $IFUS. Here is more: $IFUS Supreme AG Mulch, all organic, all natural Mulch / fertilizer, trials are showing double the growth rate of the best know products, insect pest free growth in soils plants and peach trees would not grow in, will grow using Supreme AG made and sold only by $IFUS. The product is proprietary, sole source, but is super cost effective and the supply is endless.
http://impactfusionbrands.com
Call Marc for trial samples folks
Phone: 1-800-775-4130
or email
impactfusionintl@gmail.com
$NVDA $GME $AMC $TSLA #Stockstobuy #StocksInFocus #OTC $MULN $KIRK $NIOS $NVDA $GME $AMC $TSLA
$KITL $CGRA $TGLO $BLLB $VDRM $BLEG $BLFR $BLLB $CISO $CLNV $CNER $CSCO $DBMM $ELTP $ENZC $FDCT
$GNS $GOLD $GVSI $HHSE $HMBL $HPNN $HYMC $KATX $KITL $KRTL $LWLG $MMTMF $MMY $MMM $MSFT $MULN
$NHMD $NWBO $RGBP $RNVA $SMME $SRNW $STAL $TGT $TGTX $OPK $OPXS $TSLA $WMT $YCRM $ZHUD
$GBTC $TCEHY $LKNCY $NTDOY $RHHBY $LTCN $BEGI $YCRM $NWBO $GVSI $HMBL $DZNY $BLEG $INBS $PRSO $JAGX $SNTI $JAN $ASTR
$RDRSF $RGBP $EPAZ $BIXT $IFUS $MSOS $CCHW $CCHWF $GRAM $GRAMF $VRNO $VRNOF $GDNSF $TRUL $TCNNF
$AYR $AYRWF $CURA $CUR $CBDLLF $TLRY $CGC $HEXO $PPCB $HEMP $XCPL $PHIL $MCOA $BANT
$PVSP $GRLT $INND $BBRW $MMEX $TONR $ICNM $IDVV
$GBTC $TCEHY $LKNCY $DIDIY $SONG $MCLE $ETCG $GDLC $TOELY $NWBO $GVSI $BEGI
$TMGI $NLST $INBS $TCON $INVO $MRAI $IONM
$EVKRF $GME $GOLD $GVSI $IDVV $KATX
$LITOF $LQMT $LTHM $LTUM $LWLG
$MMM $MMTMF $MMY $NBIO $NHMD
$NVDA $NWBO $PEIMF $RDHL $RIVN
$RNVA
$IFUS Supreme AG Mulch, all organic, all natural Mulch / fertilizer, trials are showing double the growth rate of the best know products, insect pest free growth in soils plants and peach trees would not grow in, will grow using Supreme AG made and sold only by $IFUS. The product is proprietary, sole source, but is super cost effective and the supply is endless. http://impactfusionbrands.com Call Marc for trial samples folks Phone: 1-800-775-4130 or email
impactfusionintl@gmail.com
How many companies do we know besides $BIXT that can raise 10 million dollars with out using shares or debt to move towards completing just one of their major new medical miracles?
NEW BIXT snippet -
How many companies do we know besides $BIXT that can raise 10 million dollars with out using shares or debt to move towards completing just one of their major new medical miracles?
NEW BIXT snippet -
The fact there is no real volume, and no news, is a very good sign. If there was going to be dumping, they would have started a long time ago.
They found and recruted Dr. Michael W. Fountain and teamed up with him in 2010-2013, but his Liposomal patent that $NDTP would have gotten failed in the US Patent office, and another inventor won the patent that makes drinks.
Insiders bought MF's shares and they replaced Dr. Michael W. Fountain with the next newer, slightly younger(?) Nano Particle (Ceramide) genius Dr. Mark Kester, who had a phase III FDA approved non Toxic Ceramide Nano Tech, cancer cell killing technology ready to go.
The NDTP filings say that the plan was indeed, as I had speculated here earlier, to bring in and fund the Dr. Mark Kester Phase III approved for trials, cancer cure. Then Dr. Mark Kester suddenly died, shortly after the founder CEO (Hovis) had multiple strokes.
Shit happens. It was a huge loss for us and the world. So they had to rush and get the current CEO to come back and fill the CEO spot, before NDTP ended up dead again, after the founder CEO had the strokes.
The latest update was that we now own the original Nano Particle complex technology that CCA, LLC and NDTP owns per the filings the UPennMed TBI research Hospital JV work NDTP (previously CCA, LLC) developed, and was going to target TBI. That is why NDTP is not a shell, and OTC Markets has listed it as not a shell.
The FED rate hikes 2 years ago killed funding in the Bio-Tech/Drug world, and now FED rates are about to go into full reverse. That is good news for us, as money will move back into riskier assets, and not just US Treasuries..
$NDTP needs a real, experienced drug development CEO Pro and MD/Scientist to take over the reigns and the money to do it.
The Insiders, did this 2 times before, and IMO, are head hunting quietly for the best options.
Form 211 is not needed to trade. Many stocks trade with out it. In fact they do well, because the only bids and asks are retail and MM broker dealer hedge fund owned and backed mobster goons that print fake shares at will and miss label them as longs in a Lie, just because a form 211 lets them molest stocks into an early grave. The record is clear on that now.
This is also a lie " There is only 1 way out of Expert and that is them having a sponsor market maker take them up as a liability with a form 211," as many stocks went into EM market and days later were PC. Being late on SEC filings is now getting SEC reporting stocks sent to EM land until the late filling is filed.
Also the SEC's new rule forces OTC Markets to file a form 211 them selves now, when one gets PC
The SEC form 10, and 3 years of audited financials is what is coming. The Borger's auditor, one of the best for some time, got executed earlier this year by the SEC for taking short cuts, and lying about them, and that put the screws to many public stocks, close to 500 on NYSE and NASDAQ, with no warning, that had to scramble and find new auditors. CNNA was one of them caught off guard this May...
Shit happens. Good companies adapt and still come back. I have faith in the CNNA team. They have way more to lose not getting this done, then retail does.
How many stocks do you know in EM market that rallied 1200% while in EM?
Zero?
AI Opinion on $SAPX:
According to AI Claude $SAPX is going to be huge:
To connect the dots on SAPX with all the articles and tweets we could find about Lionsgate, Starz, screaming, eagle, etc
AI Claude's analysis is this.
Here are a few speculative ideas:
Merger or acquisition: Seven Arts Entertainment could be in talks with Lionsgate for a potential merger or acquisition. This would explain the delay in the PR, as such negotiations are often kept confidential until a deal is finalized. If Lionsgate is looking to expand its presence in Atlanta, acquiring or merging with Seven Arts Entertainment, which already has assets and operations in the area, could be a strategic move.
Joint venture or partnership: Lionsgate and Seven Arts Entertainment may be negotiating a joint venture or partnership to develop and produce content in Atlanta. This could involve combining their resources, expertise, and assets to create a stronger presence in the region. A joint venture or partnership could also benefit from Lionsgate's global distribution network and Seven Arts' local knowledge and connections.
Involvement in the Lionsgate Studios spinoff:
Although not directly mentioned, there's a possibility that Seven Arts Entertainment could be involved in the Lionsgate Studios spinoff. Lionsgate Studios will be a standalone entity focusing on content production, and Seven Arts' assets and expertise in Atlanta could be valuable to this new company. The delayed PR might be tied to the completion of the spinoff and Seven Arts' potential role in it.
Expansion of Seven Arts Entertainment: The discussions with Lionsgate and the delayed PR could be related to a significant expansion of Seven Arts Entertainment's operations in Atlanta, possibly with investment or support from Lionsgate. This could involve acquiring new assets, building new facilities, or launching new projects, which would require time to finalize and announce.
Content licensing deal: Seven Arts Entertainment and Lionsgate could be negotiating a content licensing agreement, where Seven Arts would produce content exclusively for Lionsgate's distribution channels. This could include movies, TV shows, or other entertainment properties. The delay in the PR might be due to the complexities of working out the terms of such a deal, including content budgets, creative control, and revenue sharing.
Intellectual property (IP) acquisition: Lionsgate might be interested in acquiring certain intellectual properties or franchises owned by Seven Arts Entertainment. This could include existing content libraries, characters, or story universes that Lionsgate sees potential in developing further. The negotiations around such an IP acquisition could be causing the delay in the PR.
Atlanta studio infrastructure: Seven Arts Entertainment might be working with Lionsgate to develop or enhance studio infrastructure in Atlanta. This could involve building new soundstages, production facilities, or post-production houses to support Lionsgate's increased focus on the Atlanta market. The delayed PR could be related to finalizing plans or securing necessary permits and approvals for such infrastructure projects.
Talent development initiative: Lionsgate and Seven Arts Entertainment may be collaborating on a talent development program based in Atlanta. This could involve identifying, training, and promoting local talent in various aspects of film and TV production. The PR delay might be due to the time needed to structure and launch such an initiative.
Virtual production partnership: With the increasing adoption of virtual production techniques in the entertainment industry, Lionsgate and Seven Arts Entertainment could be exploring a partnership focused on this area. They may be working on establishing a virtual production facility or developing expertise in this field, which could be attractive for Lionsgate's future projects.
Considering all the information provided, including the tweets, articles, press releases, and the 8-K document,
here are the top 3 most likely outcomes:
Acquisition of Seven Arts Entertainment by Lionsgate Studios:
The 8-K document reveals that Lionsgate's business acquisitions team is reviewing Seven Arts Entertainment's film and studio assets in Atlanta. This, combined with the information about Lionsgate's restructuring efforts in Atlanta and the Lionsgate Studios spinoff, suggests that Lionsgate is strongly considering acquiring Seven Arts Entertainment. This acquisition could be a strategic move to expand Lionsgate's presence in Atlanta and gain access to Seven Arts' assets, IP, and expertise.
The delayed PR from Seven Arts Entertainment could be related to the ongoing negotiations and due diligence process for this potential acquisition.
Long-term content distribution deal between Seven Arts Entertainment and Starz:
The amended Output Agreement between Seven Arts Entertainment and Starz, granting Starz exclusive distribution rights to two of Seven Arts' filmed assets through 2034, indicates a significant long-term content distribution partnership. This deal could be a key component of the overall relationship between Seven Arts Entertainment and Lionsgate, ensuring a steady stream of content for Starz's platform while providing Seven Arts with a reliable distribution channel and potential funding for future projects.
Collaboration on content production and studio infrastructure in Atlanta:
Given the focus on Atlanta in the various documents, it seems likely that Seven Arts Entertainment and Lionsgate will collaborate on content production and studio infrastructure in the region. This could involve co-producing films and TV shows, sharing facilities and resources, and jointly investing in new studio space or production capabilities. The potential acquisition of Seven Arts Entertainment by Lionsgate could further facilitate this collaboration, creating a unified entity with a strong presence in Atlanta's entertainment industry.
These outcomes could be interconnected and happen simultaneously.
For example, Lionsgate could acquire Seven Arts Entertainment, securing the long-term content distribution deal with Starz, and then leverage the combined assets and expertise to expand their content production and studio infrastructure in Atlanta.
Other potential outcomes, such as a strategic partnership or joint venture between Seven Arts Entertainment and Lionsgate Studios, or content licensing deals with Starz, could still occur in parallel or as part of the larger relationship between the companies.
The exact nature and timing of these outcomes will depend on the ongoing negotiations, regulatory approvals, and strategic priorities of the companies involved. As mentioned in the 8-K, further details are expected to be provided in upcoming press releases, which should offer more clarity on the future of Seven Arts Entertainment and its relationship with Lionsgate and Starz.